Immune, Inflammatory and Fibrotic Diseases
Represent a significant unmet need that can lead to chronic organ damage and dysfunction due to abnormal immune responses and persistent inflammation. These conditions often result in debilitating symptoms and a diminished quality of life for patients.
Precision Medicine Approach
We anticipate leveraging advanced machine learning to identify patients with elevated PDE4 activity to enhance the responder population in our lead program targeting Ulcerative Colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, we hope to identify top PDE4-effector genes, which would enable us to predict potential patient responses to PDE4 inhibitors, ensuring targeting and effective treatment.
Development Programs
Differentiated prodrug candidates initially targeting established IBD market with potential to address shortcomings of existing therapies
Your tooltip content goes here
Your tooltip content goes here
PALI-2108
Indication
Ulcerative Colitis
Status
IND/CTA-Enabling
Highlights
IND/CTA-enabling tox studies completed and CTA submitted
Rapidly advancing towards first patient dosed in Phase 1 of healthy and UC patients in 2024
PALI-1908
Indication
Fibro Stenotic Crohn’s Disease
Status
Discovery
Highlights
Significant overlap with PALI-2108
POC for fibrosis pathway engagement completed
Press Releases
Sign up for Email Alerts
Stay up-to-date on our news, events and filings